Companies /Healthcare

Biogen Inc

NASDAQ: BIIB Drug Manufacturers - General
$219.05
▲ $3.04 (+1.41%) today
Markets closed · 8:31pm ET
Today · % change

24/7 Wall St. View

Fundamentals

Market Cap
$31.9B
P/E Ratio
38.4
Profit Margin
8.3%
Revenue (TTM)
$10.0B
EPS (TTM)
$5.62
52-Week Range
$135 – $226
Street Target
$237.19

About Biogen

Biogen Inc. is a pioneer in the biotechnology sector, focusing on developing treatments for neurological and neurodegenerative conditions. With a global presence, Biogen offers a range of therapies for diseases such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's. Its portfolio includes well-known drugs like TECFIDERA, SPINRAZA, and ADUHELM. Additionally, Biogen is involved in creating biosimilars, which are essentially generic versions of biologic drugs, expanding its impact on healthcare. Founded in 1978 and based in Cambridge, Massachusetts, Biogen continues to push the boundaries of medicine through innovation and partnerships.

BIIB Coverage